New University of Pittsburgh research points to a potential approach to reducing the risk of diabetes associated with widely-prescribed antipsychotic medications. The study presents early evidence in support of co-administering antipsychotic medications that block dopamine receptors in the brain alongside drugs that stop antipsychotics from blocking those same receptors in the pancreas. This approach, published in Diabetes, could limit metabolic side effects, including impaired control over blood sugar, or dysglycemia. This research may also explain why weight control medications, including new neuropeptide drugs Wegovy and Ozempic, may not be as Read More